Menelas N. Pangalos net worth and biography

Menelas Pangalos Biography and Net Worth

Director of Absci

Prof Sir Menelas Pangalos, Ph.D. has served as a member of our board of directors since January 2024. Sir Pangalos previously served as AstraZeneca's Executive Vice-President of R&D BioPharmaceuticals from January 2019 to March 2024 and in various Executive Vice-President roles for AstraZeneca since 2010. Prior to joining AstraZeneca, Sir Pangalos held senior R&D roles, including Senior Vice President, at Pfizer, Wyeth Research and GlaxoSmithKline. In 2019, Sir Pangalos was awarded a knighthood from Her Majesty The Queen of the United Kingdom of Great Britain and Northern Ireland. Sir Pangalos holds Honorary Doctorates from Glasgow University and Imperial College, London, is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. Sir Pangalos has taught as a Visiting Professor of Neuroscience at Kings College in the Wolfson Centre for Age-Related Diseases since 2005. Sir Pangalos was also an Adjunct Professor of Neuroscience from 2007 to 2010 at the Institute of Neurological Sciences at Penn University. Sir Pangalos received a Ph.D. in Neurochemistry and undergraduate degree in Biochemistry from the University of London.

What is Menelas N. Pangalos' net worth?: The estimated net worth of Menelas N. Pangalos is at least $316.81 thousand as of September 22nd, 2025. Pangalos owns 113,960 shares of Absci stock worth more than $316,809 as of March 27th. This net worth estimate does not reflect any other assets that Pangalos may own. Learn More about Menelas N. Pangalos' net worth.
How do I contact Menelas N. Pangalos?: The corporate mailing address for Pangalos and other Absci executives is , , . Absci can also be reached via phone at 360-949-1041 and via email at [email protected]. Learn More on Menelas N. Pangalos' contact information.
Has Menelas N. Pangalos been buying or selling shares of Absci?: Menelas N. Pangalos has not been actively trading shares of Absci in the last ninety days. Most recently, on Monday, September 22nd, Menelas N. Pangalos bought 95,785 shares of Absci stock. The stock was acquired at an average cost of $2.66 per share, with a total value of $254,788.10. Following the completion of the transaction, the director now directly owns 113,960 shares of the company's stock, valued at $303,133.60. Learn More on Menelas N. Pangalos' trading history.
Who are Absci's active insiders?: Absci's insider roster includes Todd Bedrick (VP), Andreas Busch (Insider), Zachariah Jonasson (Chief Financial Officer & Chief Business Officer), Sarah Korman (General Counsel), Sean Mcclain (Insider), Karen Mcginnis (Director), and Menelas Pangalos (Director). Learn More on Absci's active insiders.
Are insiders buying or selling shares of Absci?: In the last year, Absci insiders bought shares 4 times. They purchased a total of 255,785 shares worth more than $662,788.10. In the last year, insiders at the sold shares 1 times. They sold a total of 26,761 shares worth more than $80,015.39. The most recent insider tranaction occured on March, 12th when insider Andreas Busch bought 100,000 shares worth more than $229,000.00. Insiders at Absci own 10.5% of the company. Learn More about insider trades at Absci.
Information on this page was last updated on 3/12/2026.

Menelas N. Pangalos Insider Trading History at Absci

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/22/2025	Buy	95,785	$2.66	$254,788.10	113,960

Menelas N. Pangalos Buying and Selling Activity at Absci

Absci Company Overview

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Today's Range

Now: $2.78

$2.73

$2.96

50 Day Range

MA: $2.77

$2.30

$3.16

2 Week Range

Now: $2.78

$2.01

$5.23

Volume

4,200,475 shs

Average Volume

3,671,176 shs

Market Capitalization

$425.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12